Esophagogastric variceal bleeding in cirrhotic portal hypertension: Consensus on prevention and management (2008)

Chinese Medical Journal

Volumn 122, Issue 7, 2009, Pages 766-775

  Cheng, Liu Fang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CEPHALOSPORIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FRESH FROZEN PLASMA; HISTAMINE H2 RECEPTOR ANTAGONIST; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE; NADOLOL; NIFEDIPINE; NITRATE; OCTREOTIDE; PHENTOLAMINE; PITUITRIN; PLACEBO; PROPRANOLOL; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOMATOSTATIN; SOMATOSTATIN 14; SOMATOSTATIN DERIVATIVE; SPIRONOLACTONE; TERLIPRESSIN; VAPREOTIDE; VASOPRESSIN;

ARTICLE; ARTIFICIAL EMBOLISM; BLOOD TRANSFUSION; CLINICAL TRIAL; CONSENSUS; CONTINUOUS INFUSION; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; ENDOSCOPIC THERAPY; ERECTILE DYSFUNCTION; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS SURGERY; ESOPHAGUS VARICES BLEEDING; EVIDENCE BASED MEDICINE; FATIGUE; FLUID RESUSCITATION; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INFECTION; INTESTINE ISCHEMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NAUSEA; PORTAL HYPERTENSION; PREVALENCE; PRIMARY PREVENTION; RISK BENEFIT ANALYSIS; RISK FACTOR; SECONDARY PREVENTION; TACHYCARDIA; THROMBOCYTE TRANSFUSION; TINNITUS; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; UNSPECIFIED SIDE EFFECT;

ENDOSCOPY, DIGESTIVE SYSTEM; ESOPHAGEAL AND GASTRIC VARICES; FIBROSIS; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERTENSION, PORTAL;

EID: 68249149031     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.07.002     Document Type: Article

References (37)

1. de Franchis R, Pascal JP, Ancona E, Burroughs AK, Henderson M, Fleig W, et al. Definitions, methodology and therapeutic strategies in portal hypertension. A consensus development workshop. J Hepatol 1992; 15: 256-261.
2. Chinese Society of Digestive Endoscopy. Trial scheme of diagnosing and treating esophagogastric varices under endoscopy (2003). Chin J Dig Endosc (Chin) 2004; 21: 149-151.
3. Cheng LF, LI L, Wang HZ. Sclerotherapy for gastric variceal bleeding. Chin J Intern Med (Chin) 1992; 31: 87-89.
4. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent esophagogastric varices in patients with cirrhosis. N Engl J Med 2005; 353: 2254-2261.
5. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43: 167-176.
6. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of esophagogastric varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 922-938.
7. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999; 19: 475-505.
8. Lay CS, Tsai YT, Lee FY, Lai YL, Yu CJ, Chen CB, et al. Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis. J Gastroenterol Hepatol 2006; 21: 413-419.
9. Chinese Society of Hepatology, Chinese Society of Infectious Diseases. The guideline of prevention and treatment for chronic hepatitis B. Chin J Hepatology (Chin) 2005; 13: 881-891.
10. Chinese Society of Hepatology, Chinese Society for Infectious Diseases and Parasitosis. The guideline of prevention and treatment for chronic hepatitis C. Chin J Hepatology (Chin) 2004; 12: 194-198.
11. D'Amico G, Pietrosi G, Tarantino I, Pagliaro L. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology 2003; 124: 1277-1291.
12. Jiannis V, Anastasios K, Christos T, Viazis N, Sgouros S, Manolakopoulos A, et al. The effect of somatostatin versus octreotide in preventing the post-endoscopic increase of HVPG in cirrhotics with bleeding varices. Aliment Pharmacol Ther 2007; 26: 1479-1487.
13. Corley DA, Cello JP, Adkisson W, Ko WF, Kerlikowske K. Octreotide for acute esophageal variceal bleeding: a meta-analysis. Gastroenterology 2001; 120: 946-954.
14. Kong HQ, Yang DH. The evaluation of octreotide in esophagogastric variceal bleeding. Chin J Hepatology (Chin) 1995; 3: 225-226.
15. Bernard B, Grange JD, Khac EN, Ko WF, Kerlikowske K. Antibiotic prophylaxis for the prevention of bacterial infection in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29: 1655-1661.
16. Avgerinos A, Armonis A. Balloon tamponade technique and efficacy in variceal haemorrhage. Scand J Gastroenterol Suppl 1994; 207: 11-16.
17. Xie PY. Hemostasis by Sangstaken-Blakemore tube. In: Wang LH, Xu GR, Zhang SJ, eds. Handbook of internal medicine: diagnosis and management. Beijing: Medical Publishing House in Beijing University; 2001: 1066-1067.
18. Bañares R, Albillos A, Rincón D, Alonso S, González M, Ruiz-del-Arbol L, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002; 35: 609-615.
19. Cheng LF, Wang ZQ, Li CZ, Cai FC, Huang QY, Linghu EQ, et al. Treatment of gastric varices by endoscopic sclerotherapy using butyl cyanoacrylate: 10 years' experience of 635 cases. Chin Med J 2007; 120: 2081-2085.
20. Kok K, Bond RP, Duncan IC, Fourie PA, Ziady C, van den Bogaerde JB, et al. Distal embolization and local vessel wall ulceration after gastric variceal obliteration with N-butyl-2-cyanoacrylate: a case report and review of the literature. Endoscopy 2004; 36: 442-446.
21. Kleber G, Steudel N, Fleig WE. Endoscopic treatment for portal hypertension. Digestion 1998; 59 Suppl 2: s50-s53.
22. Triantos CK, Goulis J, Patch D, Papatheodoridis GV, Leandro G, Samonakis D, et al. An evaluation of emergency sclerotherapy of varices in randomized trials: looking the needle in the eye. Endoscopy 2006; 38: 797-807.
23. Cheng L, Wang Z, Li C, Cai F, Linghu E, Mao Y, et al. Experience in sclerotherapy for esophagogastric variceal bleeding. Chin Med J 2002; 115: 919-922.
24. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of esophagogastric varices and variceal bleeding. Hepatology 1985; 5: 419-424.
25. de la Pena J, Orive A, Cuadrado A, Garcia Alles L, Castro B, Rivero M. Comparison of esophageal stenoses produced by endoscopic sclerotherapy versus variceal ligation. Gastroenterol Hepatol 2006; 29: 523-527.
26. Urso G, Interlandi D, Puglisi M, Di Prima P, Bertino G, La Rosa G. The combined endoscopic therapy (band ligation and sclerosis) in the eradication of the esophageal varices in the cirrhotic patient: our experience. Minerva Gastroenterol Dietol 2006; 52: 309-316.
27. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of esophagogastric varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol 2007; 102: 2086-2102.
28. Noh DY, Park SY, Joo SY. Therapeutic effect of the endoscopic N-butyl-2-cyanoacrylate injection for acute esophagogastric variceal bleeding: comparison with transjugular intrahepatic portosystemic shunt. Korean J Gastroenterol 2004; 43: 186-195.
29. Working group of Interventional Therapy of the editorial board of Chinese Journal of Radiology. The guideline on transjugular intrahepatic portosystemic shunt. Chin J Radiol (Chin) 2004; 36: 1329-1331.
30. LaBerge JM. Transjugular intrahepatic portosystemic shunt - role in treating intractable variceal bleeding, ascites, and hepatic hydrothorax. Clin Liver Dis 2006; 10: 583-598.
31. Eisen GM, Eliakim R, Zaman A, Schwartz J, Faigel D, Rondonotti E, et al. The accuracy of PillCam ESO capsule endoscopy versus conventional upper endoscopy for the diagnosis of esophageal varices: a prospective three-center pilot study. Endoscopy 2006; 38: 31-35.
32. Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997; 25: 63-70.
33. De la Pena J, Brullet E, Sanchez-Hernandez E, Rivero M, Vergara M, Martin-Lorente JL, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005; 41: 572-578.
34. Spahr L, Giostra E, Frossard J-L, Morard I, Mentha G, Hadengue A. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. Am J Gastroenterol 2007; 102: 1397-1405.
35. Zhang XX, Xu K. Transjungular intrahepatic portal-systemic shunt. In: Xu K, Zou YH, Ou YY, eds. Intraluminal stent-assisted therapy. Beijing: Scientific Publishing House; 2004: 417.
36. Sonomura T, Sato M, Kishi K, Terada M, Shioyama Y, Kimura M, et al. Balloon-occluded retrograde transvenous obliteration for gastric varices: a feasibility study. Cardiovasc Intervent Radiol 1998; 21: 27-30.
37. Hirota S, Kobayashi K, Maeda H, Yamamoto S, Nakao N. Balloon-occluded retrograde transvenrous obliteration for portal hypertension. Radiat Med 2006; 24: 315-320.